menu

MENU

繁體中文

Contact Us

Menu

Menu

Company

Introduction
Team & Board of Directors
Partners
Investors
Latest News

R&D Pipeline

Overview
Intranasal Vaccines
Asthma Immunotherapy
Respiratory Antiviral Immunotherapy

Company

Introduction

Team & Board of Director

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Contact us

Latest News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

October 3, 2023

The Company Announces Phase IIa Clinical Trial Results of Investigational New Drug AD17002-SC for COVID-19, Demonstrating Statistically Significant Efficacy in Accelerating Viral Clearance with a Favorable Safety and Tolerability Profile.

Updates

October 3, 2023

【經濟日報】昱厚鼻噴新冠藥臨床二a解盲 有效抑制病毒、縮短病程

Press

July 4, 2023

【中時新聞網】《興櫃股》昱厚雙管齊下 今年加速臨床試驗與商務拓展

Press

June 30, 2023

【環球生技月刊】昱厚鼻噴新冠藥台灣臨床Q3解盲、將辦現增1~2.4億新台幣加速臨床

Press

June 30, 2023

【經濟日報】昱厚聚焦三新藥開發 將辦現增加速臨床試驗推展

Press